Industry
Biotechnology
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Loading...
Open
3.40
Mkt cap
98M
Volume
83K
High
3.44
P/E Ratio
-1.14
52-wk high
7.22
Low
3.22
Div yield
N/A
52-wk low
1.88
Portfolio Pulse from Benzinga Newsdesk
September 17, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Newsdesk
September 17, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 30, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 4:50 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:55 pm
Portfolio Pulse from Avi Kapoor
June 05, 2024 | 12:40 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:21 pm
Portfolio Pulse from Happy Mohamed
March 19, 2024 | 8:33 pm
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 8:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.